Sign In
Buy APVO
$5.02
-0.0200 (-0.397%)
At Close: Jun 03, 2026
The
Aptevo Therapeutics Reports Second Quarter 2020 Financial Results
01:00pm, Friday, 14'th Aug 2020
* Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Complete * Presents New Preclinical Data Showin
Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust | | IT Business Net
03:11pm, Thursday, 06'th Aug 2020
Extends Cash Runway into Q3 2021 The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May De
Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust
01:00pm, Thursday, 06'th Aug 2020
Extends Cash Runway into Q3 2021The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May Del
Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones
01:00pm, Tuesday, 21'st Jul 2020
SEATTLE, WA / ACCESSWIRE / July 21, 2020 / Aptevo Therapeutics Inc.
$290,000.00 in Sales Expected for Aptevo Therapeutics Inc (NASDAQ:APVO) This Quarter
01:36am, Saturday, 18'th Jul 2020
Wall Street analysts expect that Aptevo Therapeutics Inc (NASDAQ:APVO) will post $290,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates f
Top Stocks To Short As Nasdaq Sets New Intraday Record
12:00am, Monday, 13'th Jul 2020
Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the major thr
All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to Buy
04:00pm, Tuesday, 30'th Jun 2020
Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year?
03:30pm, Tuesday, 30'th Jun 2020
Is (APVO) Outperforming Other Medical Stocks This Year?
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale
01:00pm, Monday, 29'th Jun 2020
SEATTLE, WA / ACCESSWIRE / June 29, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™
Published Articles Suggest the Global Market for Rituximab Biosimilars Could Potentially be over $1 Billion Per Year Royalty Stream Relates to Agreement Acquired in Aptevo Spin-off from Emergent BioSo
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar
01:00pm, Thursday, 25'th Jun 2020
SEATTLE, WA / ACCESSWIRE / June 25, 2020 / Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispeci
The
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
01:00pm, Wednesday, 10'th Jun 2020
New Preclinical Data Show That ALG.APV-527 has Potential for a Favorable Safety Profile Does Not Induce Systemic T-cell Activation at High Doses Which Were Observed in a Urelumab Analogue in a Side-by
